KR20220103987A - 피라졸로-헤테로아릴 유도체, 그것의 제조 방법, 및 그것의 의학적 용도 - Google Patents
피라졸로-헤테로아릴 유도체, 그것의 제조 방법, 및 그것의 의학적 용도 Download PDFInfo
- Publication number
- KR20220103987A KR20220103987A KR1020227019663A KR20227019663A KR20220103987A KR 20220103987 A KR20220103987 A KR 20220103987A KR 1020227019663 A KR1020227019663 A KR 1020227019663A KR 20227019663 A KR20227019663 A KR 20227019663A KR 20220103987 A KR20220103987 A KR 20220103987A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- alkyl
- heterocyclyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911147956 | 2019-11-21 | ||
| CN201911147956.3 | 2019-11-21 | ||
| CN202010837381.4 | 2020-08-19 | ||
| CN202010837381 | 2020-08-19 | ||
| PCT/CN2020/130326 WO2021098811A1 (zh) | 2019-11-21 | 2020-11-20 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220103987A true KR20220103987A (ko) | 2022-07-25 |
Family
ID=75981069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227019663A Ceased KR20220103987A (ko) | 2019-11-21 | 2020-11-20 | 피라졸로-헤테로아릴 유도체, 그것의 제조 방법, 및 그것의 의학적 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559488B2 (https=) |
| EP (1) | EP4063363A4 (https=) |
| JP (1) | JP7781059B2 (https=) |
| KR (1) | KR20220103987A (https=) |
| CN (5) | CN120004887A (https=) |
| AU (1) | AU2020386587A1 (https=) |
| BR (1) | BR112022008000A2 (https=) |
| CA (1) | CA3159376A1 (https=) |
| MX (1) | MX2022005985A (https=) |
| TW (1) | TW202128690A (https=) |
| WO (1) | WO2021098811A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112142744A (zh) | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| TW202220993A (zh) * | 2020-08-07 | 2022-06-01 | 香港商德琪研發有限公司 | Atr抑制劑及其用途 |
| WO2022135560A1 (en) * | 2020-12-25 | 2022-06-30 | Impact Therapeutics (Shanghai) , Inc | Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof |
| KR20240012471A (ko) | 2021-05-21 | 2024-01-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피라졸로헤테로아릴계 유도체의 약학적으로 허용 가능한 염 및 이의 결정형 |
| WO2023109883A1 (zh) * | 2021-12-15 | 2023-06-22 | 上海翊石医药科技有限公司 | 一类芳杂环取代的化合物及其制备方法和用途 |
| WO2024109727A1 (zh) * | 2022-11-21 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 |
| CN119143753B (zh) * | 2023-06-14 | 2026-01-02 | 石药集团中奇制药技术（石家庄）有限公司 | 一种杂环类抗肿瘤化合物的盐及其晶型 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| CA2819373A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US20190000850A1 (en) | 2015-02-09 | 2019-01-03 | The Regents Of The University Of California | Combination cancer therapy |
| WO2017118734A1 (en) | 2016-01-08 | 2017-07-13 | The Institute Of Cancer Research: Royal Cancer Hospital | Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer |
| CA3011189C (en) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| US11730734B2 (en) | 2016-09-12 | 2023-08-22 | University Of Florida Research Foundation, Incorporated | Use of ATR and Chk1 inhibitor compounds |
| WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| EP3679041B1 (en) | 2017-09-08 | 2022-07-06 | Newave Pharmaceutical Inc. | Substituted pyrrolopyridines as atr inhibitors |
| CN112654396B (zh) * | 2018-09-07 | 2025-07-01 | 默克专利股份公司 | 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物 |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
-
2020
- 2020-11-20 TW TW109140787A patent/TW202128690A/zh unknown
- 2020-11-20 CN CN202510105110.2A patent/CN120004887A/zh active Pending
- 2020-11-20 BR BR112022008000A patent/BR112022008000A2/pt unknown
- 2020-11-20 AU AU2020386587A patent/AU2020386587A1/en active Pending
- 2020-11-20 JP JP2022529505A patent/JP7781059B2/ja active Active
- 2020-11-20 MX MX2022005985A patent/MX2022005985A/es unknown
- 2020-11-20 WO PCT/CN2020/130326 patent/WO2021098811A1/zh not_active Ceased
- 2020-11-20 CN CN202510104960.0A patent/CN120004872A/zh active Pending
- 2020-11-20 CN CN202080066108.4A patent/CN114423760B/zh active Active
- 2020-11-20 KR KR1020227019663A patent/KR20220103987A/ko not_active Ceased
- 2020-11-20 CN CN202510105174.2A patent/CN120004888A/zh active Pending
- 2020-11-20 US US17/778,632 patent/US12559488B2/en active Active
- 2020-11-20 EP EP20890856.6A patent/EP4063363A4/en active Pending
- 2020-11-20 CN CN202510105045.3A patent/CN120004886A/zh active Pending
- 2020-11-20 CA CA3159376A patent/CA3159376A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023502458A (ja) | 2023-01-24 |
| CN114423760A (zh) | 2022-04-29 |
| CN120004886A (zh) | 2025-05-16 |
| WO2021098811A1 (zh) | 2021-05-27 |
| EP4063363A1 (en) | 2022-09-28 |
| TW202128690A (zh) | 2021-08-01 |
| AU2020386587A1 (en) | 2022-06-02 |
| BR112022008000A2 (pt) | 2022-07-12 |
| CN120004872A (zh) | 2025-05-16 |
| EP4063363A4 (en) | 2023-11-29 |
| JP7781059B2 (ja) | 2025-12-05 |
| CN120004888A (zh) | 2025-05-16 |
| CA3159376A1 (en) | 2021-05-27 |
| US20230018728A1 (en) | 2023-01-19 |
| CN120004887A (zh) | 2025-05-16 |
| MX2022005985A (es) | 2022-06-17 |
| US12559488B2 (en) | 2026-02-24 |
| CN114423760B (zh) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781059B2 (ja) | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 | |
| CA3172285A1 (en) | Fused imidazole derivatives, preparation method and medical use thereof | |
| KR20240089594A (ko) | 질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 | |
| RU2717577C2 (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| BR112019017108A2 (pt) | derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos | |
| KR20130110149A (ko) | 프탈라지논 케톤 유도체, 이의 제조방법, 및 이의 약학적 용도 | |
| KR20240012437A (ko) | 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용 | |
| KR20230042057A (ko) | 황-함유 이소인돌린 유도체, 및 이의 제조 방법 및 이의 의학적 용도 | |
| CN113518779B (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| TW201835079A (zh) | ６－吡唑－［１，２，４］三唑並［４，３－α］吡啶－３－醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN112574212B (zh) | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| CN115867552B (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| CN113004303A (zh) | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 | |
| CA3186193A1 (en) | Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof | |
| HK40070277B (zh) | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| HK40070277A (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| CN110964034B (zh) | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 | |
| WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| CN120098001A (zh) | 作为细胞周期蛋白依赖性激酶抑制剂的噻吩类化合物及其制备方法和医药用途 | |
| CN103958501B (zh) | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 | |
| CN114634522A (zh) | 嘌呤酮衍生物、其制备方法及其在医药上的应用 | |
| CN113135942A (zh) | 稠合嘧啶类衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |